Cargando…
Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated he...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852959/ https://www.ncbi.nlm.nih.gov/pubmed/35175577 http://dx.doi.org/10.1007/s40620-022-01245-9 |
_version_ | 1784653138507071488 |
---|---|
author | Wand, Ori Nacasch, Naomi Fadeela, Ayman Shashar, Moshe Grupper, Ayelet Benchetrit, Sydney Erez, Daniel Shitrit, Pnina Cohen-Hagai, Keren |
author_facet | Wand, Ori Nacasch, Naomi Fadeela, Ayman Shashar, Moshe Grupper, Ayelet Benchetrit, Sydney Erez, Daniel Shitrit, Pnina Cohen-Hagai, Keren |
author_sort | Wand, Ori |
collection | PubMed |
description | INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated hemodialysis patients. METHODS: Patients on maintenance hemodialysis who received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were analysed according to having developed COVID-19 (study group) or not (control group), in a retrospective, observational, comparative study. We compared risk-factors for developing breakthrough COVID-19 and assessed clinical outcomes, including 30-day mortality rates. RESULTS: Twenty-four cases of breakthrough SARS-CoV-2 infection were compared to 91 controls without infection. Breakthrough infection was associated with chronic immunosuppressive treatment, hematological malignancies, and low antibody levels against SARS-CoV-2 spike protein. All COVID-19 cases occurred at least 5 months after vaccination, and most were caused by the B.1.617.2 variant (at least 23/24 cases). COVID-19 was categorized as severe or critical disease in 11/24 patients (46%), and 54% required hospitalization and COVID-19-directed treatment. The source of infection was nosocomial in 6/24 cases (25%), and healthcare-related in 3/24 (12.5%). Mortality rate was 21%. Overall mortality was significantly higher in patients who developed COVID-19 than in controls (odds ratio for all-cause mortality 7.6, 95% CI 1.4–41, p = 0.002). CONCLUSIONS: Breakthrough COVID-19 with the B.1.617.2 variant can occur in vaccinated hemodialysis patients and is associated with immunosuppression and weaker humoral response to vaccination. Infections may be nosocomial and result in significant morbidity and mortality. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-022-01245-9. |
format | Online Article Text |
id | pubmed-8852959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88529592022-02-18 Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients Wand, Ori Nacasch, Naomi Fadeela, Ayman Shashar, Moshe Grupper, Ayelet Benchetrit, Sydney Erez, Daniel Shitrit, Pnina Cohen-Hagai, Keren J Nephrol original Article INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated hemodialysis patients. METHODS: Patients on maintenance hemodialysis who received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were analysed according to having developed COVID-19 (study group) or not (control group), in a retrospective, observational, comparative study. We compared risk-factors for developing breakthrough COVID-19 and assessed clinical outcomes, including 30-day mortality rates. RESULTS: Twenty-four cases of breakthrough SARS-CoV-2 infection were compared to 91 controls without infection. Breakthrough infection was associated with chronic immunosuppressive treatment, hematological malignancies, and low antibody levels against SARS-CoV-2 spike protein. All COVID-19 cases occurred at least 5 months after vaccination, and most were caused by the B.1.617.2 variant (at least 23/24 cases). COVID-19 was categorized as severe or critical disease in 11/24 patients (46%), and 54% required hospitalization and COVID-19-directed treatment. The source of infection was nosocomial in 6/24 cases (25%), and healthcare-related in 3/24 (12.5%). Mortality rate was 21%. Overall mortality was significantly higher in patients who developed COVID-19 than in controls (odds ratio for all-cause mortality 7.6, 95% CI 1.4–41, p = 0.002). CONCLUSIONS: Breakthrough COVID-19 with the B.1.617.2 variant can occur in vaccinated hemodialysis patients and is associated with immunosuppression and weaker humoral response to vaccination. Infections may be nosocomial and result in significant morbidity and mortality. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-022-01245-9. Springer International Publishing 2022-02-17 2022 /pmc/articles/PMC8852959/ /pubmed/35175577 http://dx.doi.org/10.1007/s40620-022-01245-9 Text en © The Author(s) under exclusive licence to Italian Society of Nephrology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | original Article Wand, Ori Nacasch, Naomi Fadeela, Ayman Shashar, Moshe Grupper, Ayelet Benchetrit, Sydney Erez, Daniel Shitrit, Pnina Cohen-Hagai, Keren Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients |
title | Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients |
title_full | Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients |
title_fullStr | Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients |
title_full_unstemmed | Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients |
title_short | Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients |
title_sort | humoral response and breakthrough infections with sars-cov-2 b.1.617.2 variant in vaccinated maintenance hemodialysis patients |
topic | original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852959/ https://www.ncbi.nlm.nih.gov/pubmed/35175577 http://dx.doi.org/10.1007/s40620-022-01245-9 |
work_keys_str_mv | AT wandori humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT nacaschnaomi humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT fadeelaayman humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT shasharmoshe humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT grupperayelet humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT benchetritsydney humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT erezdaniel humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT shitritpnina humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients AT cohenhagaikeren humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients |